Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llag164 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Marina Talamonti und 59 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy. Hauptthemen laut MEDLINE: Prurigo, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder that markedly impairs quality of life. Dupilumab, an interleukin-4Rα antagonist, is approved for moderate-to-severe PN, but long-term real-world evidence remains limited.
Objectives
To evaluate the long-term effectiveness and safety of dupilumab in adults with PN, including those with multiple comorbidities, in a real-world multicentre setting.
Methods
Clinical data were collected from 26 Italian dermatology centres [the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study]. Adults with PN refractory to topical therapies and/or phototherapy, and/or prior systemic treatments who received dupilumab for a minimum treatment duration of 12 weeks were included. Outcomes routinely assessed in practice – Worst Itch (WI) Numeric Rating Scale (NRS) (WI-NRS), Investigator Global Assessment for PN-Stage (IGA PN-S), Sleep-NRS, Skin Pain-NRS and Dermatology Life Quality Index (DLQI) – were analysed at baseline and weeks 12, 24, 52, 76 and 104. Main endpoints were ≥ 4-point WI-NRS reduction and IGA PN-S 0/1 status. Predictors of response and safety were also evaluated.
Results
In total, 543 patients [mean age 65.7 (SD 15.8) years; 63.7% (346/543) female] were included. Dupilumab induced rapid and sustained improvements: mean WI-NRS decreased from 8.69 (SD 1.41) to 2.67 (SD 2.59) at week 24 and to 1.72 (SD 2.44) at week 104 (P < 0.001); ≥ 4-point WI-NRS reduction was achieved by 78.6% (408/519) and by 86.9% (258/297) of patients at 24 and 104 weeks, respectively; and IGA PN-S 0/1 achieved by 62.8% (326/519) and 81.1% (241/297) of patients at 24 and 104 weeks. DLQI improved from 17.40 (SD 6.94) to 2.57 (SD 4.89) (P < 0.001). Higher baseline WI-NRS predicted better outcomes, whereas psychiatric comorbidities and prior tricyclic antidepressant use predicted lower response. Dupilumab was well tolerated; discontinuation because of adverse events occurred in 2.9% (16/543), with no cancer progression or viral reactivation.
Conclusions
Dupilumab provided sustained, clinically meaningful benefits and a favourable safety profile over 104 weeks, supporting its role as a long-term treatment for moderate-to-severe PN, including in older adults and patients with comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.
- Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
ORCID-Profile: Luigi Gargiulo, Andrea Carugno, Maria Esposito, Luca Stingeni, Federica Veronese
Zitieren
APA
Talamonti, M., Mortato, E., Narcisi, A., Ferrucci, S. M., Gargiulo, L., Marzano, A. V., Napolitano, M., Patruno, C., Rossi, M., Balato, A., Gori, N., Foti, C., Tiberio, R., Corazza, M., Carugno, A., Calabrese, L., Pezzolo, E., Esposito, M., Antiga, E., …, & Esposto, E. (2026). Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag164
Vancouver
Talamonti M, Mortato E, Narcisi A, Ferrucci SM, Gargiulo L, Marzano AV, et al. Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag164
BibTeX
@article{Talamonti2026,
author = {Talamonti, Marina and Mortato, Edoardo and Narcisi, Alessandra and Ferrucci, Silvia Mariel and Gargiulo, Luigi and Marzano, Angelo Valerio and Napolitano, Maddalena and Patruno, Cataldo and Rossi, Mariateresa and Balato, Anna and Gori, Niccolò and Foti, Caterina and Tiberio, Rossana and Corazza, Monica and Carugno, Andrea and Calabrese, Laura and Pezzolo, Elena and Esposito, Maria and Antiga, Emiliano and Trave, Ilaria and Savoia, Paola and Caroppo, Francesca and Maurelli, Martina and Musumeci, Maria Letizia and Amerio, Paolo and Stingeni, Luca and Lembo, Serena and Satta, Rosanna Rita and Russo, Filomena and Mariano, Maria and Paganini, Claudia and Costanzo, Antonio and Zussino, Martina and Del Gaudio, Marika and Stevan, Erica and Caccavale, Stefano and D'Amore, Alessandra and Tirone, Benedetta and Pertusi, Ginevra and Borghi, Alessandro and Lazzeri, Laura and Magnanimi, Lina Maria and Maglie, Roberto and Cozzani, Emanuele and Veronese, Federica and Belloni Fortina, Anna and Girolomoni, Giampiero and Micali, Giuseppe and Morea, Edvige and Hansel, Katharina and Raimondo, Annunziata and Biondi, Gabriele and Sordi, Donatella and Ibba, Luciano and Nicoletti, Maddalena and Peris, Ketty and Sbarra, Giorgia and Schettini, Natale and Loda, Alessia and Esposto, Elia},
title = {Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag164}
}
EUVIMED